Last reviewed · How we verify
Atacand/HCT, Caduet
Atacand/HCT combines an angiotensin II receptor blocker with a thiazide diuretic to reduce blood pressure through vasodilation and sodium/fluid excretion, while Caduet combines an HMG-CoA reductase inhibitor with a calcium channel blocker to lower cholesterol and blood pressure.
Atacand/HCT combines an angiotensin II receptor blocker with a thiazide diuretic to reduce blood pressure through vasodilation and sodium/fluid excretion, while Caduet combines an HMG-CoA reductase inhibitor with a calcium channel blocker to lower cholesterol and blood pressure. Used for Hypertension (Atacand/HCT), Hypertension and dyslipidemia (Caduet).
At a glance
| Generic name | Atacand/HCT, Caduet |
|---|---|
| Sponsor | Baim Institute for Clinical Research |
| Drug class | Angiotensin II receptor blocker/thiazide diuretic combination (Atacand/HCT); Calcium channel blocker/HMG-CoA reductase inhibitor combination (Caduet) |
| Target | Angiotensin II type 1 receptor, thiazide-sensitive sodium-chloride cotransporter (Atacand/HCT); L-type calcium channel, HMG-CoA reductase (Caduet) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Atacand (candesartan) blocks angiotensin II receptors to relax blood vessels and reduce vasoconstriction, while hydrochlorothiazide promotes sodium and water excretion to decrease blood volume. Caduet combines amlodipine (a dihydropyridine calcium channel blocker that dilates coronary and peripheral vessels) with atorvastatin (a statin that inhibits HMG-CoA reductase to reduce LDL cholesterol synthesis). Together these agents address both hypertension and dyslipidemia.
Approved indications
- Hypertension (Atacand/HCT)
- Hypertension and dyslipidemia (Caduet)
Common side effects
- Dizziness
- Fatigue
- Hyperkalemia (Atacand/HCT)
- Hypokalemia (Atacand/HCT)
- Muscle pain/myalgia (Caduet)
- Elevated liver enzymes (Caduet)
- Peripheral edema (Caduet)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atacand/HCT, Caduet CI brief — competitive landscape report
- Atacand/HCT, Caduet updates RSS · CI watch RSS
- Baim Institute for Clinical Research portfolio CI